文献速递痛风与晶体性关节病

美国≥50岁成年人暴露于重组带状疱疹疫苗后新发痛风的风险

Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years.
PubMed 文献 · Semin Arthritis Rheum · 2024-07-14

本研究采用自身对照风险区间设计,基于美国行政理赔数据纳入≥50岁、暴露于重组带状疱疹疫苗(RZV)后60天内新发痛风的302例个体,比较暴露后第1-30天(风险窗)与第31-60天(对照窗)的痛风风险。结果风险窗153例(50.7%)vs 对照窗149例(49.3%),RR 1.03(95%CI 0.81, 1.29),所有敏感性分析结果一致,未发现RZV与新发痛风存在关联。

要点

  • RZV暴露后第1-30天痛风事件153例(50.7%),第31-60天149例(49.3%)。
  • 风险窗对比对照窗的RR为1.03(95%CI 0.81, 1.29),未达统计学显著。
  • 剂量1、剂量2、符合60-183天推荐间隔、季节性调整及疫情前限制等敏感性分析结果一致。

核心结论

  • 在美国≥50岁人群中,与后续30天对照窗相比,RZV暴露后立即30天内痛风风险无统计学显著增加(RR 1.03;95%CI 0.81, 1.29)。

研究设计与样本

  • 采用自身对照风险区间(SCRI)设计的真实世界回顾性安全性研究,使用行政理赔数据。
  • 纳入≥50岁、有RZV暴露且60天内新发痛风的健康计划成员;风险窗为暴露后第1-30天,对照窗为第31-60天。
  • 共461,323人接受≥1剂RZV,SCRI分析纳入302例新发痛风个体(平均年龄72.5岁;66%男性)。

主要发现

  • 风险窗痛风事件153例(50.7%),对照窗149例(49.3%);RR 1.03(95%CI 0.81, 1.29)。
  • 剂量1、剂量2特异性风险、符合60-183天推荐剂量间隔者、季节性调整及限制于COVID-19前时代(2019年12月1日前)的敏感性分析结果均一致,未显示RZV与新发痛风存在关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether recombinant zoster vaccine (RZV) is associated with an increased risk of new-onset gout among US adults aged ≥50 years. METHODS: We conducted a real-world, retrospective safety study with a self-controlled risk interval (SCRI) design using administrative claims data. We included health plan members aged ≥50 years with RZV exposure, followed by incident gout within 60 days. Days 1-30 following RZV exposure were considered the risk window (RW), and days 31-60 were considered the control window (CW). We estimated the risk ratio (RR) of gout in the RW versus CW, using a conditional Poisson model. The primary analysis estimated the risk of incident gout following any RZV dose. Sensitivity analyses evaluated dose 1- and dose 2-specific risks, risk among patients compliant with recommended dose spacing of 60-183 days, adjustment for seasonality, and restriction to the pre-COVID-19 era (before December 1, 2019). RESULTS: A total of 461,323 individuals received ≥1 RZV dose; we included 302 individuals (mean age 72.5 years; 66 % male) with evidence of new-onset gout within 60 days in SCRI analyses. A total of 153 (50.7 %) individuals had gout events in the RW and 149 (49.3 %) in the CW (RR 1.03; 95 % confidence interval 0.81, 1.29). All sensitivity analyses had consistent results, with no association of RZV with incident gout. CONCLUSION: In a population of US adults aged ≥50 years, there was no statistically significant increase in the risk of gout during the 30 days immediately after RZV exposure, compared with a subsequent 30-day CW.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kluberg SA, Simon AL, Alam SM, et al. Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years. Semin Arthritis Rheum. 2024. PMID: 39079205. doi:10.1016/j.semarthrit.2024.152518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。